Paramit’s board of directors is comprised of top executives in global business as well as the medical field. They help us understand the challenges and opportunities of ongoing FDA guideline development, the market implications of new technologies, and the adoption path of those technologies.
George E. Aitken-Davies, Managing Director, Altaris Capital Partners, LLC
A founding partner of Altaris Capital Partners, LLC, an investment firm focused exclusively on companies operating in the healthcare industry, George is responsible for sourcing, analyzing, executing, and monitoring private equity transactions and he serves on the board of directors for a number of Altaris portfolio companies. Prior to Altaris, George worked at Merrill Lynch where he was a member of the firm’s private equity and healthcare investment banking group. With a Masters in Molecular and Cellular Biochemistry from the University of Oxford, George investigated the metabolism of bovine prion protein for his research dissertation.
Jim O’Brien, Principal, Altaris Capital Partners, LLC
Jim is a Principal at Altaris Capital Partners, LLC, an investment firm focused exclusively on companies operating in the healthcare industry. At Altaris, Jim is responsible for sourcing, analyzing, executing, and monitoring private equity transactions and he serves on the board of directors for a number of Altaris portfolio companies. Prior to Altaris, Jim worked at Merrill Lynch where he executed mergers and acquisitions and corporate finance transactions as part of the firm’s investment banking and equity capital markets groups. Jim received a B.A. in History from Princeton University.
Bernard E. Lyons, Ph.D., Executive Consultant, Direct Flow Medical, Inc.
Bernie is the former President and CEO of Direct Flow Medical, Inc., a medical device company specializing in transcathter aortic valve implants. Throughout his career Bernie has held senior level management positions at a number of medical device companies, including Vasca, Inc. (President and CEO), a maker of subcutaneous vascular access ports for hemodialysis treatment, CardioClasp, Inc. (President and CEO), a start-up focused on the treatment of congestive heart failure, and Boston Scientific Corporation, a large manufacturer of diagnostic and therapeutic products. Bernie has been an Instructor in Surgery at Dartmouth Medical School and Adjunct Assistant Professor at the Thayer School of Engineering at Dartmouth College. He earned a Ph.D. in Cancer Biology from Stanford University School of Medicine.
William (Bill) E. Rhodes, III, Founding Member, Third Day Advisors, LLC.
Bill is the founding member of Third Day Advisors LLC, a management and strategy advisory firm to life science companies. Bill is also the Senior Executive in Residence at Cornell University’s McGovern Life Sciences Center and a Clinical Instructor with Weill Cornell Medical College’s Department of Healthcare Policy and Research. Prior to Third Day Advisors, Bill was an Executive Officer and SVP, Business Development & Strategy for Becton Dickinson and Co. (BD) and before that he was their Worldwide President, BD Biosciences. Prior to joining BD, he held various senior executive positions with Pfizer, J&J, Reed and Carnrick Pharmaceuticals and The William James Company. Bill holds an M.S. in International Business from Seton Hall University and a B.S. in entomology from Cornell University.
Carl joined Paramit in 1992. He developed Paramit’s test infrastructure, including both test development and all levels of test and reliability into a core company strength. While at Paramit, Carl managed all engineering and quality functions. Prior to Paramit, Carl spent seven years at LTX-Trillium in Test Engineering and Development positions. He has a BSEE from Santa Clara University.